Educational use only — not medical advice. This guide summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.
Gonadorelin at a glance
- What it is
- Synthetic gonadotropin-releasing hormone (GnRH), a 10-amino-acid peptide identical to the endogenous hypothalamic hormone
- Approved for
- Historically FDA-approved (as Factrel) for diagnostic testing of pituitary gonadotropin reserve; that product has been withdrawn and no FDA-approved human product is currently marketed in the US
- Commonly reported range
- ~50-200 mcg per injection in community and research reports (not a recommendation)
- Route reported
- Subcutaneous injection most commonly; intravenous used in clinical/diagnostic settings
- Reported frequency
- 2-3 times weekly in TRT-adjunct reports; pulsatile pump protocols dose every 60-120 minutes clinically
- Reported cycle
- Often used continuously alongside exogenous testosterone in community reports; clinical pulsatile use is protocol-defined
- Plasma half-life
- Very short: ~2-10 min distribution, ~10-40 min terminal
- Regulatory status
- Not an FDA-approved marketed human drug in the US (research/compounded only); WADA-prohibited (S2) in males
Reported ranges from research/community — examples, not recommendations.
What it is / mechanism
Gonadorelin is a synthetic decapeptide with the identical amino acid sequence to endogenous gonadotropin-releasing hormone (GnRH). It is reported to act as an agonist at GnRH receptors on the anterior pituitary gonadotroph cells, prompting release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). In turn, LH and FSH are reported to signal the gonads to produce testosterone and support spermatogenesis in males, and to regulate follicular development and ovulation in females. A defining feature described in the literature is frequency dependence: pulsatile delivery that mimics natural hypothalamic secretion (roughly every 60-120 minutes) is reported to sustain gonadotropin output, whereas continuous exposure paradoxically downregulates and desensitizes the receptor, suppressing LH and FSH. Its very short half-life is central to this behavior, causing each dose to act as a brief pulse rather than a sustained signal.
Researched effects
In research and clinical reports, gonadorelin has been associated with acute increases in circulating LH and FSH following a pulse, and pulsatile administration has been used to attempt restoration of hypothalamic-pituitary-gonadal (HPG) axis signaling in hypogonadotropic hypogonadism. In community TRT-adjunct discussions it is reported to be used in an attempt to maintain testicular signaling during exogenous testosterone use, as an alternative to hCG. These are research findings and community reports, not guaranteed outcomes; individual responses vary and much of the non-diagnostic use is off-label or research-context only.
Evidence & regulatory status
- Clinical evidence: gonadorelin's ability to acutely stimulate LH and FSH release is well documented, and pulsatile GnRH delivery has been studied for inducing puberty and fertility in hypogonadotropic hypogonadism; the diagnostic gonadorelin stimulation test is long established.
- Regulatory: the historical human product (Factrel) was FDA-approved for diagnostic pituitary testing but has been withdrawn from the market; there is currently no FDA-approved marketed human gonadorelin product in the US, and material is typically compounded or sold for research.
- Research-use framing: TRT-adjunct and bodybuilding uses described in community sources are not FDA-approved indications and are reported as examples, not validated protocols or recommendations.
Dosage — reported ranges (overview)
The following are examples of what is reported in community and research sources, not a recommendation or personal dose. TRT-adjunct reports commonly describe roughly 50-100 mcg subcutaneously two to three times weekly, while some bodybuilding sources describe 100-200 mcg per administration. Clinical pulsatile fertility protocols instead use an infusion pump delivering small doses (often ~5-20 mcg) every 60-120 minutes. Because of the receptor-desensitization concern, community sources frequently caution against continuous high-frequency self-dosing. Any real-world use should be directed by a qualified clinician.
A printable protocol sheet with a reconstitution reference and an injection log comes with All-Access Lifetime.
Reconstitution — bac-water math
Reconstitution is concentration math only, not a personal dose. Gonadorelin is dosed in micrograms (mcg), so the useful figure is mcg per milliliter. With a vial of V mg and W mL of bacteriostatic water, concentration = (V x 1000) / W mcg/mL. On a U-100 insulin syringe, 100 units = 1 mL, so units for a dose D (mcg) = round(D / concentration x 100). Worked example: a 2 mg vial reconstituted with 2 mL of water gives 1000 mcg/mL; a 100 mcg dose is 100 / 1000 x 100 = 10 units on a U-100 syringe.
| Bac water added | Concentration | 100 mcg example dose | 200 mcg example dose |
|---|
| 1 mL | 2000 mcg/mL | 5 units (0.05 mL) | 10 units (0.10 mL) |
| 2 mL | 1000 mcg/mL | 10 units (0.10 mL) | 20 units (0.20 mL) |
| 3 mL | 667 mcg/mL | 15 units (0.15 mL) | 30 units (0.30 mL) |
This is concentration math, not a dose recommendation.
Injection / administration basics
In reports, gonadorelin is most commonly given as a small-volume subcutaneous injection using a U-100 insulin syringe, with the reconstituted solution drawn from a multi-use vial. Community sources describe rotating injection sites (abdomen, flank) and standard aseptic handling: swabbing the vial stopper and injection site with alcohol before each use. This section describes reported handling practices for research context and is not medical instruction or a recommendation to self-inject.
Half-life & frequency rationale
Gonadorelin has a very short plasma half-life: distribution half-life is reported at roughly 2-10 minutes and terminal half-life at roughly 10-40 minutes. This rapid clearance is why the peptide behaves as a brief pulse and why dosing frequency, rather than dose size alone, is reported to determine whether the pituitary is stimulated or suppressed.
Side effects, safety & contraindications
Reported effects in clinical use include injection-site reactions (pain, redness, swelling), headache, flushing, nausea, and lightheadedness; rare hypersensitivity and, historically with pump use, occasional local infection have been reported. Because much non-diagnostic use is off-label with limited long-term human safety data, the desensitization risk from overly frequent or continuous dosing is a commonly cited concern. This is a summary of reported findings, not a complete safety profile; a clinician should evaluate any individual situation.
Stacking — overview
Gonadorelin is most often discussed in the context of male hormonal support rather than growth or repair, so its reported pairings differ from typical peptide stacks. In community TRT-adjunct discussions it is described alongside exogenous testosterone as a way people attempt to keep the HPG axis engaged. Growth-hormone secretagogues are sometimes listed in the same overall regimen because they act on a separate axis. The following are reported combinations for educational context, not recommendations.
HPG-axis support (community-reported)
Gonadorelin + Kisspeptin-10
GH-axis add-on (separate axis)
Gonadorelin + CJC-1295 + Ipamorelin
GH-axis add-on
Gonadorelin + Sermorelin
Recovery-oriented regimen
Gonadorelin + BPC-157 + TB-500
Stacking across compounds
The overview above covers Gonadorelin. The cross-compound material — which pairings are redundant rather than additive, where interaction risk is documented versus merely unstudied, and the blend arithmetic worked end to end — lives in the Peptide Stacking Guide, which is free to read in outline and $39 in full (included with All-Access Lifetime).
Included with this guide
The Gonadorelin Stacking Module
The overview above is the free summary. The Gonadorelin Stacking Module goes through each combination in depth — the mechanism-level reason it is proposed, what is actually reported in practice, and the cautions specific to that pairing — plus what to avoid and why. Included with Gonadorelin Standard Access.
- How to think about stacking Gonadorelin — 4 principles
- 3 combinations covered in detail
- What to avoid, and why — 3 items
- Combination-specific cautions
Combinations covered: HPG-axis support (community-reported), GH-axis add-on, Recovery-oriented regimen.
For how combinations are grouped by research context, the named blends, and why a pre-mixed blend vial cannot be calculated from its total milligrams, see the peptide stacks guide.
Storage & handling
- Lyophilized (powder): reported stable refrigerated at 2-8 C; can typically be kept at room temperature short-term and away from light per common handling guidance.
- Reconstituted (in bacteriostatic water): refrigerate at 2-8 C, protect from light, and use within a few weeks per community-reported handling; discard if cloudy or discolored.
References
Compiled from public pharmacology references, historical FDA labeling for Factrel (gonadorelin hydrochloride), the WADA Prohibited List, and community-reported use; provided for educational purposes only and not as medical advice.
Related peptide guides
Continue exploring related educational guide topics in the Medibact library.
Guide FAQ
Quick answers about guide scope, access, and educational use context.
Is gonadorelin the same as GnRH?
Yes. Gonadorelin is a synthetic decapeptide with the identical amino acid sequence to endogenous gonadotropin-releasing hormone (GnRH). This is educational information, not medical advice.
Why does dosing frequency matter so much?
Reports emphasize that pulsatile delivery (spaced doses) stimulates LH and FSH, whereas continuous or very frequent exposure can downregulate and desensitize the GnRH receptor, paradoxically suppressing gonadotropins. This is a widely described pharmacological feature, not dosing guidance.
How is gonadorelin different from hCG?
hCG mimics LH and acts directly on the gonads, while gonadorelin acts upstream at the pituitary to prompt the body's own LH and FSH release. Community sources describe both as testicular-support options; this is reported context, not a recommendation.
Is gonadorelin FDA-approved?
The historical human product (Factrel) was FDA-approved for diagnostic pituitary testing but has been withdrawn; there is currently no FDA-approved marketed human gonadorelin product in the US. Material is typically compounded or sold for research.
Is gonadorelin banned in sport?
Yes. GnRH and its agonists, including gonadorelin, are prohibited in males under WADA category S2. Athletes subject to anti-doping rules should treat it as prohibited.
Compliance and trust notes
- Educational content only; no personalized health or outcome claims.
- No personalized use recommendation outputs.
- Use this material for general learning and research-context literacy.
